Intercalated regimen demonstrates first-line efficacy for advanced NSCLC
Administration of erlotinib in combination with chemotherapy is a viable first-line treatment strategy in patients with advanced non-small-cell lung cancer, results from FASTACT-2 suggest.
No comments:
Post a Comment